Tenaya Therapeutics (TNYA) Competitors $1.83 +0.06 (+3.39%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.87 +0.04 (+2.19%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. DNTH, NBTX, PRAX, COLL, PHAR, UPB, SPRY, RAPP, SYRE, and SANAShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Dianthus Therapeutics (DNTH), Nanobiotix (NBTX), Praxis Precision Medicines (PRAX), Collegium Pharmaceutical (COLL), Pharming Group (PHAR), Upstream Bio (UPB), ARS Pharmaceuticals (SPRY), Rapport Therapeutics (RAPP), Spyre Therapeutics (SYRE), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Dianthus Therapeutics Nanobiotix Praxis Precision Medicines Collegium Pharmaceutical Pharming Group Upstream Bio ARS Pharmaceuticals Rapport Therapeutics Spyre Therapeutics Sana Biotechnology Dianthus Therapeutics (NASDAQ:DNTH) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Do insiders and institutionals have more ownership in DNTH or TNYA? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, DNTH or TNYA? Dianthus Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500. Does the media refer more to DNTH or TNYA? In the previous week, Dianthus Therapeutics and Dianthus Therapeutics both had 3 articles in the media. Tenaya Therapeutics' average media sentiment score of 0.99 beat Dianthus Therapeutics' score of 0.34 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend DNTH or TNYA? Dianthus Therapeutics currently has a consensus price target of $61.57, indicating a potential upside of 77.18%. Tenaya Therapeutics has a consensus price target of $6.25, indicating a potential upside of 241.53%. Given Tenaya Therapeutics' higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has preferable valuation and earnings, DNTH or TNYA? Dianthus Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M179.26-$84.97M-$3.25-10.69Tenaya TherapeuticsN/AN/A-$111.13M-$0.96-1.91 Is DNTH or TNYA more profitable? Tenaya Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-2,364.56% -34.72% -32.72% Tenaya Therapeutics N/A -93.83%-75.66% SummaryTenaya Therapeutics beats Dianthus Therapeutics on 8 of the 14 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$288.47M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-1.9121.5785.4827.61Price / SalesN/A271.42535.60201.12Price / CashN/A47.1237.9261.55Price / Book1.7110.1412.976.76Net Income-$111.13M-$52.31M$3.30B$275.88M7 Day Performance14.38%5.14%4.35%2.81%1 Month Performance40.77%14.68%9.50%9.24%1 Year Performance6.40%30.98%84.38%35.42% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.2879 of 5 stars$1.83+3.4%$6.25+241.5%+5.8%$288.47MN/A-1.91110News CoverageAnalyst ForecastDNTHDianthus Therapeutics2.9469 of 5 stars$34.46-1.4%$61.57+78.7%+24.2%$1.11B$6.24M-10.6080Analyst ForecastNBTXNanobiotix1.2692 of 5 stars$22.78+11.1%$11.00-51.7%+423.2%$1.09B$39.18M0.00100Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumePRAXPraxis Precision Medicines2.2582 of 5 stars$50.98-6.3%$85.56+67.8%-16.2%$1.07B$8.55M-4.15110News CoverageAnalyst ForecastCOLLCollegium Pharmaceutical4.1521 of 5 stars$33.83-2.3%$42.33+25.1%-12.9%$1.07B$631.45M32.53210News CoveragePositive NewsAnalyst ForecastPHARPharming Group2.3119 of 5 stars$15.38-4.7%$30.00+95.1%+69.5%$1.05B$339.84M-118.31280Analyst ForecastShort Interest ↑UPBUpstream Bio1.8817 of 5 stars$18.97+1.8%$56.50+197.8%N/A$1.02B$2.72M0.0038Analyst ForecastSPRYARS Pharmaceuticals2.9139 of 5 stars$10.27-0.4%$33.17+222.9%-20.0%$1.01B$112.34M-20.9690Analyst ForecastRAPPRapport Therapeutics3.0183 of 5 stars$27.74-2.8%$35.33+27.4%+37.3%$1.01BN/A-11.10N/AAnalyst ForecastGap UpSYRESpyre Therapeutics3.2735 of 5 stars$16.67+4.9%$54.29+225.6%-36.6%$1.01B$890K-4.9073Analyst DowngradeSANASana Biotechnology2.5942 of 5 stars$4.16+5.1%$7.50+80.3%+11.0%$989.29MN/A-3.92380Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Dianthus Therapeutics Competitors Nanobiotix Competitors Praxis Precision Medicines Competitors Collegium Pharmaceutical Competitors Pharming Group Competitors Upstream Bio Competitors ARS Pharmaceuticals Competitors Rapport Therapeutics Competitors Spyre Therapeutics Competitors Sana Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
